Category: Thoratec Corp.Syndicate content

A tale of 2 LVADs: Thoratec gains, HeartWare slides on Q1 results

May 11, 2015 by Brad Perriello

Shares of Thoratec rise after the heart pump maker beats Wall Street's forecast with its 1st-quarter results, but arch-rival HeartWare slides after just meeting The Street's bottom line.

A tale of 2 LVADs: Thoratec gains, HeartWare slideson Q1 results

ConvaTec makes interim chief Moraviec CEO | Personnel Moves

May 1, 2015 by Brad Perriello

ConvaTec names interim chief executive Paul Moraviec as its permanent CEO.

ConvaTec makes interim chief Moraviec CEO | Personnel Moves

ConvaTec, which is rumored to be exploring a sale, said yesterday that it made its interim CEO, former EMEA president Paul Moraviec, to be its new permanent CEO.

Luxembourg-based ConvaTec, which is owned by private equity firms Avista Capital Partners and Nordic Capital, tapped Moraviec to lead its business in Europe, the Middle East and Africa in 2009.

LVADs: Thoratec study a Roadmap to lower-risk patients?

April 20, 2015 by Brad Perriello

Results from Thoratec's Roadmap study of its HeartMate II implantable heart pump in less-sick heart failure patients shows significant benefit over optimal medical therapy alone.

LVADs: Thoratec study a Roadmap to lower-risk patients

HeartWare slides on stroke results from heart pump studies

April 16, 2015 by Brad Perriello

Higher-than-expected stroke rates reported in a pair of studies of HeartWare's implantable heart pump this week spook investors, pushing HTWR share prices down more than 8%.

HeartWare slides on stroke results from heart pump studies

FDA OKs expanded HeartMate III trial for Thoratec

April 2, 2015 by Brad Perriello

The FDA approves an expansion of the clinical trial for Thoratec's next-generation implantable heart pump, the HeartMate III device.

FDA OKs expanded HeartMare III trial for Thoratec

Thoratec's Q4, 2014 earnings beat forecasts

February 11, 2015 by Brad Perriello

Thoratec reports higher-than-forecast earnings for the 4th quarter and 2014, on an extra selling week and higher utilization rates for its implantable heart pumps, and says it will narrow its focus to the ventricular assist device market.

Thoratec's Q4, 2014 earnings beat forecasts

Thoratec (NSDQ:THOR) yesterday reported higher-than-forecast earnings for the 4th quarter and 2014, crediting an extra selling week and better utilization rates for its implantable heart pumps.

Thoratec completes enrollment in HeartMate III study

December 1, 2014 by Val Kennedy

Thoratec completes enrollment in a European clinical trial for its HeartMate III left ventricular assist device.

Thoratec completes enrollment in HeartMate III study